Heron Therapeutics | HRTX - Bénéfice Avant Impôts

Prix De L'Action
0.80
Variation Quotidienne
0.02 2.05%
Mensuellement
-27.06%
Annuel
-67.28%
Q1 Prévisions
0.76




Bénéfice Avant Impôts Changement Date
ALKERMES USD 100.74M 4.1M 2025-09
Alnylam Pharmaceuticals USD 161.14M 77.83M 2025-12
Amarin USD -852K 7.26M 2025-12
ANI Pharmaceuticals USD 49.52M 39M 2025-09
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD 28.27M 7.85M 2025-12
Eisai JPY 22B 7.47B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
GlaxoSmithKline GBP 1.23B 1.23B 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Insmed USD -326.93M 41.77M 2025-12
Ligand Pharmaceuticals USD 141.14M 102M 2025-09
Merck USD 6.74B 22M 2025-09
Nektar Therapeutics USD -37.05M 15.27M 2024-09
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Omeros USD -65.12M 21.27M 2024-06
Pacira USD 9.52M 11.45M 2025-09
Regeneron Pharmaceuticals USD 1.76B 244.6M 2025-09
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Surmodics USD -7.51M 1.69M 2024-09
Ultragenyx Pharmaceutical USD -128M 51.54M 2025-12
Veracyte USD 40.63M 21.74M 2025-12
Vertex Pharmaceuticals USD 1.3B 15.8M 2025-09